HOMEABOUT MEDAFINANCIAL INFORMATIONNEWSPRODUCTSCONTACT US

NEWS

  

Year 2008

Change in the number of shares of MEDA AB2008-12-30 15:00 - Pressrelease - pdf
First combination of NSAID and proton pump inhibitor approved2008-12-09 13:23 - Pressrelease - pdf
Retigabine – positive results in Phase III study2008-12-08 16:00 - Pressrelease - pdf
New share issue oversubscribed2008-11-28 13:20 - Pressrelease - pdf
Extended employment for CEO2008-11-28 11:55 - Pressrelease - pdf
CEO increases shareholding in Meda2008-11-17 10:49 - Pressrelease - pdf
European collaboration agreement in dermatology2008-11-17 09:02 - Pressrelease - pdf
Nomination committee appointed2008-11-07 15:46 - Pressrelease - pdf
Public notification regarding availability of Meda’s 2008 new share issue prospectus2008-11-05 15:50 - Pressrelease - pdf
Misleading information about Meda’s share price from Six2008-11-03 14:04 - Pressrelease - pdf
Bulletin from the Meda AB (publ) extraordinary general meeting (EGM) approving decision to issue shares2008-10-31 16:24 - Minutes of extraordinary general meeting - pdf
Meda AB (publ), Interim Report January – September 20082008-10-31 08:00 - Quarterly report - pdf
FDA has accepted for filing the first potential once-a-day nasal antihistamine2008-10-24 11:34 - Pressrelease - pdf
The FDA approves Astepro2008-10-17 08:51 - Pressrelease - pdf
Guaranteed new share issue with preferential rights2008-10-14 08:00 - Pressrelease - pdf
Acquisition of product portfolio from Roche completed2008-10-02 08:00 - Pressrelease - pdf
Extended collaboration with Recordati in Spain2008-10-01 13:30 - Pressrelease - pdf
Acquisition of European businesses from Valeant completed2008-09-12 08:00 - Pressrelease - pdf
Retigabine agreement can give Meda significant royalty income2008-08-28 14:33 - Pressrelease - pdf
Anticipated approval of OnsolisTM during first half 2009 following receipt of Complete Response letter from FDA2008-08-28 14:00 - Pressrelease - pdf
Meda has settled the U.S. Astelin patent litigation with Cobalt2008-08-25 08:10 - Pressrelease - pdf
Meda acquires product portfolio from Roche2008-08-15 07:30 - Pressrelease - pdf
Meda AB (publ) January – June 2008, H1 interim report2008-08-08 08:00 - Half Year financial report - pdf
Meda enters into joint venture with Valeant2008-08-07 08:00 - Pressrelease - pdf
Registration application for azelastine Extra Strength submitted to the FDA2008-08-04 09:14 - Pressrelease - pdf
Meda acquires European businesses from American Valeant and enters the Russian market2008-08-04 08:00 - Pressrelease - pdf
The FDA has accepted for filing the registration application for Sublinox2008-07-29 08:12 - Pressrelease - pdf
FDA approves azelastine eye drops unit dose2008-07-08 13:41 - Pressrelease - pdf
FDA requests more information on new azelastine formulation2008-06-03 22:02 - Pressrelease - pdf
Sublinox registration application submitted to the FDA2008-05-15 08:00 - Pressrelease - pdf
Meda AGM bulletin2008-05-06 20:40 - Minutes of annual general meeting - pdf
Meda AB (publ), January – March 2008 interim report2008-05-06 08:00 - Quarterly report - pdf
Meda has settled the U.S. Astelin® patent litigation with Apotex2008-04-21 09:16 - Pressrelease - pdf
Meda has settled the U.S. Astelin® patent litigation with Apotex2008-04-21 09:02 - Pressrelease - pdf
Meda and Orexo in a potential billion SEK deal2008-04-14 08:00 - Pressrelease - pdf
Notice of annual general meeting (AGM)2008-04-03 15:00 - Notice to convene annual general meeting - pdf
Meda AB (publ) – 2007 year-end report2008-02-26 08:00 - Annual Financial Statement - pdf
Change in the number of Meda AB shares2008-01-31 15:54 - Changes in share capital and votes - pdf